Among the control cohort, these patients are likely pursuing other interventions (e.g., lifestyle, diet, exercise) in addition to medications aside from GLP-1s that could lead them to see beneficial results
Genetic variants in FTO , GLP1R (the receptor semaglutide targets), MC4R , and TCF7L2 describe baseline appetite regulation, energy balance, and glucose handling at the pathway level
In addition, they can be expensive and have side effects that reduce the overall quality of life and compliance of patients
This may limit the generalizability to younger populations, who have a lower baseline risk of AF/Aflutter and stroke [79, 80]
Therefore, given the lack of comprehensive understanding of the risks to breastfeeding infants, medical practitioners and health care providers generally recommend against the use of Ozempic during breastfeeding, except in cases where the medicinal benefits greatly surpass the potential risks